Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Medivation, Inc
Man Max 99 years
Medivation, Inc
Update Il y a 4 ans
An International Study to Evaluate the effectiveness of continuing treatment of enzalutamide after PSA Progression in Patients who have not yet received chemotherapy
To determine the efficacy of combination treatment with continued enzalutamide plus abiraterone acetate (abiraterone) and prednisone (or prednisolone) compared with placebo plus abiraterone and predni...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Medivation, Inc
Update Il y a 4 ans
HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease(Protocol DIM20EXT)
• To evaluate the long-term safety of dimebon (latrepirdine) in Huntington disease (HD) subjects who have successfully completed 26 weeks of blinded treatment in the HORIZON protocol (DIM20).
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Medivation, Inc
Update Il y a 4 ans
CONNECTION PLUS: An Open-Label Extension of the CONNECTION Protocol (DIM14) Evaluating Oral Dimebon in Patients with Alzheimer’s Disease
To evaluate the long-term safety and tolerability of Dimebon in Alzheimer’s Disease (AD) patients who have successfully completed 26 weeks of blinded treatment in the CONNECTION protocol (DIM14).
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Medivation, Inc
Update Il y a 4 ans
CONNECTION: A Global Phase 3, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Oral Dimebon in Patients with Mild-to-Moderate Alzheimer’s Disease
• To determine the benefit of Dimebon as compared to placebo on the primary measure of cognition and memory, the Alzheimer’s Disease Assessment Scale – cognitive subscale (ADAS-cog); and • To determin...
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Medivation, Inc
Update Il y a 4 ans
An international study to evaluate the effectiveness of Talazoparib in men with a genomic defect and metastatic castration-resistant prostate cancer who received previous chemotherapy and progressed on hormonal treatment
To evaluate efficacy, as measured by best objective response rate (ORR)
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Medivation, Inc
Update Il y a 4 ans
An open label study to provide extended treatment in patients treated with Talazoparib
To offer extended open label treatment to patients treated with talazoparib in qualifying studies To obtain additional safety data on talazoparib use
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Medivation, Inc
Update Il y a 4 ans
A MULTI-CENTER, PHASE 2 RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF DIMEBON IN SUBJECTS WITH HUNTINGTON’S DISEASE
To assess the safety and tolerability of Dimebon, 20 mg three times a day (TID), during 90 days of treatment in subjects with Huntington’s disease (HD).
Country
None
organs
None
Specialty
None
unknown
More information
Woman Max 99 years
Medivation, Inc
Update Il y a 4 ans
A Multinational Study to Evaluate the Safety and Activity of Enzalutamide in Combination With Exemestane in Women With Hormone-Positive Breast Cancer That Is Normal for HER-2
To determine the benefit of exemestane plus enzalutamide versus exemestane plus placebo as assessed by progression free survival (PFS) in patients with advanced breast cancer that is estrogen and/or p...
Country
None
organs
None
Specialty
None
unknown
More information
Woman Max 99 years
Medivation, Inc
Update Il y a 4 ans
A Multinational Study to Evaluate the Safety and Activity of Enzalutamide in Women Whose Breast Cancer Expresses the Androgen Receptor but Does Not Express Estrogen or Progesterone Receptors, and is Not Amplified for the Epidermal Growth Factor Receptor, HER2 Un ensayo multinacional para evaluar la seguridad y la actividad de Enzalutamida en mujeres con cáncer que expresa el receptor de andrógenos pero no los receptores de estrógenos o progesterona, y no está amplificado por el receptor del factor de crecimiento epidérmico HER2
The primary objective is to determine clinical benefit rate in patients with AR+ triple-negative breast cancer (TNBC). El objetivo principal es determinar la tasa de beneficio clínico en pacient...
Country
None
organs
None
Specialty
None
unknown
More information
Man Max 99 years
Medivation, Inc
Update Il y a 4 ans
A multinational study to evaluate the safety and effectiveness of enzalutamide in patients whose prostate cancer has not metastasized
To determine the efficacy of enzalutamide compared with placebo as assessed by metastasis free survival (MFS).
Country
None
organs
None
Specialty
None
unknown
More information
1
2
Next